Vote Scores

Home / Companies / Hikma Pharmaceuticals Plc / 23 Apr 2026

Meeting · year to 30 June 202682 filers reporting

Hikma Pharmaceuticals Plc: meeting of 23 Apr 2026

Votes reported on Form N-PX, item by item

82 Form N-PX filers reported votes at the Hikma Pharmaceuticals Plc meeting of 23 Apr 2026. Their records fall into 8 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

9 nominees; 97.5% of reported votes for; 6 filers withheld from or voted against at least one nominee.

1,017 vote records from 69 filers. 1 of the 67 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

97.1% for1.4% against1.4% other1.5% against management69 filers
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

88 vote records from 22 filers. 0 of the 17 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.

77.3% for0.0% against22.7% other0.0% against management22 filers100.0% for0.0% against0.0% against management26,678,695 reported shares
3

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

226 vote records from 69 filers. 0 of the 67 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

98.6% for0.0% against1.4% other0.0% against management69 filers100.0% for0.0% against0.0% against management49,269,346 reported shares
4

SHAREHOLDER RIGHTS AND DEFENSESIssuer

SHAREHOLDER RIGHTS AND DEFENSES: management items

Management items in this category are shown together; filers word and number them differently.

238 vote records from 69 filers. 0 of the 67 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

98.6% for0.0% against1.4% other0.0% against management69 filers100.0% for0.0% against0.0% against management51,659,503 reported shares, counted once per item in this group
5

CAPITAL STRUCTUREIssuer

CAPITAL STRUCTURE: management items

Management items in this category are shown together; filers word and number them differently.

565 vote records from 69 filers. 0 of the 67 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

98.6% for0.0% against1.4% other0.0% against management69 filers99.9% for0.1% against0.1% against management123,173,365 reported shares, counted once per item in this group
6

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

197 vote records from 68 filers. 0 of the 66 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

98.5% for0.0% against1.5% other0.0% against management68 filers100.0% for0.0% against0.0% against management39,154,796 reported shares, counted once per item in this group
7

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

206 vote records from 69 filers. 0 of the 67 filers that marked the item either way voted against management. 2 filers reported this item without a management mark.

92.8% for0.0% against7.2% other0.0% against management69 filers99.2% for0.8% against0.8% against management41,525,291 reported shares, counted once per item in this group
8

OTHERIssuer

OTHER: management items

Management items in this category are shown together; filers word and number them differently.

24 vote records from 6 filers. 0 of the 6 filers that marked the item either way voted against management.

100.0% for0.0% against0.0% against management6 filers100.0% for0.0% against0.0% against management5,353,898 reported shares, counted once per item in this group

How the largest families voted

Family1. Directors2. Say-on-pay3. Auditor
VanguardForNo reportFor
BlackRock and iSharesForForFor
FidelityForNo reportFor
DimensionalForNo reportFor
State Street and SPDRForNo reportFor
American CenturyForNo reportFor
InvescoForNo reportFor
Charles SchwabForNo reportFor
Nuveen and TIAAForNo reportFor
John Hancock and ManulifeForForFor
Morgan Stanley, Eaton Vance and CalvertForNo reportFor
Goldman SachsForNo reportFor
PGIM and PrudentialAgainst *No reportFor
Northern Trust and FlexSharesForForFor
SEIForNo reportFor
ThriventForNo reportFor
Lincoln FinancialForNo reportFor
VoyaForNo reportFor
First TrustForNo reportFor
Russell InvestmentsForNo reportFor
NationwideForNo reportFor
Victory CapitalForNo reportFor
Brighthouse FundsForNo reportFor
Columbia ThreadneedleForNo reportFor
Pacific Life fundsForNo reportFor
Hartford FundsForNo reportFor
PIMCOForNo reportFor
Lord AbbettForNo reportFor

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Hikma Pharmaceuticals Plc meeting?

82 Form N-PX filers reported votes at the meeting of 23 Apr 2026. On say-on-pay, 0 of 17 voted against management (0.0%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Hikma Pharmaceuticals Plc on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Hikma Pharmaceuticals Plc

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Hikma Pharmaceuticals Plc with a meeting date within three days of 23 Apr 2026. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.